Next Article in Journal
Design and Exploratory Neuropharmacological Evaluation of Novel Thyrotropin-Releasing Hormone Analogs and Their Brain-Targeting Bioprecursor Prodrugs
Next Article in Special Issue
The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer
Previous Article in Journal
Encapsulation of Hydrocortisone and Mesalazine in Zein Microparticles
Previous Article in Special Issue
Development of a Novel Lipophilic, Magnetic Nanoparticle for in Vivo Drug Delivery
Pharmaceutics 2013, 5(2), 294-317; doi:10.3390/pharmaceutics5020294

Delivery of Cancer Therapeutics Using Nanotechnology

2,*  and 1,*
1 Department of Radiology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea 2 Department of Chemical and Biomolecular Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-749, Korea 3 Department of Chemistry, Korea University, 145 Anam-ro, Dongdaemun-gu, Seoul 136-701, Korea
* Authors to whom correspondence should be addressed.
Received: 24 December 2012 / Revised: 15 April 2013 / Accepted: 3 May 2013 / Published: 15 May 2013
(This article belongs to the Special Issue Drug Delivery Using Nanotechnology)
View Full-Text   |   Download PDF [1014 KB, uploaded 15 May 2013]   |   Browse Figures


Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic efficacy and (iv) controlling drug release by external/internal stimuli. Because of these features, therapeutic efficacy can be improved and unwanted side effects can be reduced. Theranostic nanoparticles have been developed by incorporating imaging agents in drug carriers as all-in-one system, which makes it possible to diagnose and treat cancer by monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, activatable nanomaterials are being applied that are capable of producing chemical or physical changes by external stimuli. By using these nanoparticles, multiple tasks can be carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of patient groups of personalized therapy and real-time monitoring of disease progress. In this paper, we describe various types of nanoparticles for drug delivery systems, as well as theranostic systems.
Keywords: nanoparticles; nanotechnology; drug delivery; cancer; theranostic nanoparticles nanoparticles; nanotechnology; drug delivery; cancer; theranostic nanoparticles
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Lim, E.-K.; Jang, E.; Lee, K.; Haam, S.; Huh, Y.-M. Delivery of Cancer Therapeutics Using Nanotechnology. Pharmaceutics 2013, 5, 294-317.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert